Alterity Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alterity Therapeutics Limited
Inhibikase Back In Game As FDA Lifts Hold On Multiple System Atrophy Drug
The US FDA lifted a clinical hold that it had placed in November after reviewing the company’s INDs to start Phase IIa studies in MSA and Parkinson’s, which was the subject of a hold lifted in January.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Will Genus Claims Be Resuscitated? Supreme Court To Decide In Amgen PCSK9 Patent Dispute
High court will consider the standard for determining if a patent covering a group of related chemicals is enabled in Amgen v. Sanofi. It denies Juno petition seeking review of standard for written description of an invention in CAR T-cell patent suit against Kite.
Servier: Precision Approach To Immunotherapy Will Define New Oncology Era
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
- Other Names / Subsidiaries
- Prana Biotechnology Limited (PRAN)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.